

CADTH REIMBURSEMENT REVIEW

Stakeholder Feedback on Draft Recommendation

RIPRETINIB (Qinlock)
(Medison Pharma Canada Inc.)

Indication: For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.

April 14, 2022

Disclaimer: The views expressed in each submission are those of the submitting organization or individual; not necessarily the views of CADTH or of other organizations. As such, they are independent of CADTH and do not necessarily represent or reflect the view of CADTH. No endorsement by CADTH is intended or should be inferred.

By filing with CADTH, the submitting organization or individual agrees to the full disclosure of the information. CADTH does not edit the content of the submissions.

CADTH does use reasonable care to prevent disclosure of personal information in posted material; however, it is ultimately the submitter's responsibility to ensure no identifying personal information or personal health information is included in the submission. The name of the submitting organization or individual and all conflict of interest information are included in the submission; however, the name of the author, including the name of an individual patient or caregiver submitting the feedback, are not posted.

CADTH is committed to treating people with disabilities in a way that respects their dignity and independence, supports them in accessing material in a timely manner, and provides a robust feedback process to support continuous improvement. All materials prepared by CADTH are available in an accessible format. Where materials provided to CADTH by a submitting organization or individual are not available in an accessible format, CADTH will provide a summary document upon request. More details on CADTH's accessibility policies can be found [here](#).

CADTH Reimbursement Review

Feedback on Draft Recommendation

Stakeholder information	
CADTH project number	PC0265
Name of the drug and Indication(s)	Ripretinib for GIST
Organization Providing Feedback	PAG

1. Recommendation revisions		
Please indicate if the stakeholder requires the expert review committee to reconsider or clarify its recommendation.		
Request for Reconsideration	Major revisions: A change in recommendation category or patient population is requested	<input type="checkbox"/>
	Minor revisions: A change in reimbursement conditions is requested	<input type="checkbox"/>
No Request for Reconsideration	Editorial revisions: Clarifications in recommendation text are requested	X
	No requested revisions	<input type="checkbox"/>

2. Change in recommendation category or conditions
Complete this section if major or minor revisions are requested
None.

3. Clarity of the recommendation
Complete this section if editorial revisions are requested for the following elements
a) Recommendation rationale
In Table 2. Responses to Questions from the Drug Programs, under the heading “Considerations for discontinuation of therapy,” PAG is requesting to remove the following text” pERC noted that dosing 150 mg ripretinib orally twice daily is not approved by Health Canada. Hence, pERC cannot recommend such as use.”
b) Reimbursement conditions and related reasons
None.
c) Implementation guidance
None.

CADTH Reimbursement Review Feedback on Draft Recommendation

Stakeholder information		
CADTH project number	PC0265	
Brand name (generic)	QINLOCK™ (ripretinib)	
Indication(s)	For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.	
Organization	Medison Pharma Canada Inc.	
Contact information ^a	[REDACTED]	
Stakeholder agreement with the draft recommendation		
1. Does the stakeholder agree with the committee's recommendation.	Yes	<input checked="" type="checkbox"/>
	No	<input type="checkbox"/>
<p>Medison Pharma Canada Inc. (Medison) agrees with CADTH's draft recommendation for ripretinib.</p> <p>Medison also recognizes feedback received from the provincial advisory group (PAG), clinicians, and patient advocacy groups who have provided input and have all indicated that the reimbursement of ripretinib would fulfill a significant unmet need for a new treatment for adult patients with advanced GIST who have received prior treatment with imatinib, sunitinib, and regorafenib.</p>		
Expert committee consideration of the stakeholder input		
2. Does the recommendation demonstrate that the committee has considered the stakeholder input that your organization provided to CADTH?	Yes	<input checked="" type="checkbox"/>
	No	<input type="checkbox"/>
Clarity of the draft recommendation		
3. Are the reasons for the recommendation clearly stated?	Yes	<input checked="" type="checkbox"/>
	No	<input type="checkbox"/>
4. Have the implementation issues been clearly articulated and adequately addressed in the recommendation?	Yes	<input checked="" type="checkbox"/>
	No	<input type="checkbox"/>
5. If applicable, are the reimbursement conditions clearly stated and the rationale for the conditions provided in the recommendation?	Yes	<input checked="" type="checkbox"/>
	No	<input type="checkbox"/>

^a CADTH may contact this person if comments require clarification.